ExcelMale
Menu
Home
What's new
Latest activity
Forums
New posts
Search forums
What's new
New posts
Latest activity
Videos
Lab Tests
Doctor Finder
Buy Books
About Us
Men’s Health Coaching
Log in
Register
What's new
Search
Search
Search titles only
By:
New posts
Search forums
Menu
Log in
Register
Navigation
Install the app
Install
More options
Contact us
Close Menu
Forums
Testosterone Replacement, Low T, HCG, & Beyond
Testosterone Basics & Questions
TLANDO & TLANDO XR - novel oral prodrugs of testosterone
JavaScript is disabled. For a better experience, please enable JavaScript in your browser before proceeding.
You are using an out of date browser. It may not display this or other websites correctly.
You should upgrade or use an
alternative browser
.
Reply to thread
Message
<blockquote data-quote="madman" data-source="post: 195528" data-attributes="member: 13851"><p>[ATTACH=full]12861[/ATTACH]</p><h3></h3><h3></h3><h3>PIONEERING FOR NEXT-GENERATION ORAL TRT</h3><p></p><p><em><strong>TLANDO XR is a next-generation, novel ester prodrug of testosterone that uses the patent-protected Lip'ral technology to enhance solubility and improve systemic absorption. </strong>Lipocine completed a Phase 2b dose-finding study in hypogonadal men in 2016. The primary objectives of the Phase 2b clinical study were to determine the starting Phase 3 dose of TLANDO XR along with the safety and tolerability of TLANDO XR and its metabolites following oral administration of single and multiple doses in hypogonadal men. The Phase 2b clinical trial was a randomized, open-label, two-period, multi-dose PK study. Results suggested that the primary objectives were met, including identifying the dose expected to be tested in the planned Phase 3 study. A good dose-response relationship was observed over the tested dose range. Additionally, the target Phase 3 dose met primary and secondary endpoints. TLANDO XR was well tolerated with no drug-related severe or serious adverse events reported in the Phase 2b study.</em></p></blockquote><p></p>
[QUOTE="madman, post: 195528, member: 13851"] [ATTACH type="full" alt="Screenshot (3504).png"]12861[/ATTACH] [HEADING=2][/HEADING] [HEADING=2][/HEADING] [HEADING=2]PIONEERING FOR NEXT-GENERATION ORAL TRT[/HEADING] [I][B]TLANDO XR is a next-generation, novel ester prodrug of testosterone that uses the patent-protected Lip'ral technology to enhance solubility and improve systemic absorption. [/B]Lipocine completed a Phase 2b dose-finding study in hypogonadal men in 2016. The primary objectives of the Phase 2b clinical study were to determine the starting Phase 3 dose of TLANDO XR along with the safety and tolerability of TLANDO XR and its metabolites following oral administration of single and multiple doses in hypogonadal men. The Phase 2b clinical trial was a randomized, open-label, two-period, multi-dose PK study. Results suggested that the primary objectives were met, including identifying the dose expected to be tested in the planned Phase 3 study. A good dose-response relationship was observed over the tested dose range. Additionally, the target Phase 3 dose met primary and secondary endpoints. TLANDO XR was well tolerated with no drug-related severe or serious adverse events reported in the Phase 2b study.[/I] [/QUOTE]
Insert quotes…
Verification
Post reply
Share this page
Facebook
Twitter
Reddit
Pinterest
Tumblr
WhatsApp
Email
Share
Link
Sponsors
Forums
Testosterone Replacement, Low T, HCG, & Beyond
Testosterone Basics & Questions
TLANDO & TLANDO XR - novel oral prodrugs of testosterone
This site uses cookies to help personalise content, tailor your experience and to keep you logged in if you register.
By continuing to use this site, you are consenting to our use of cookies.
Accept
Learn more…
Top